OVID Company Profile and Key Details

Q: Who are the executives of OVID?

Dr. Matthew J. During DSc, FACP, FRACP, M.D., Ph.D.Founder & Member of Scientific Advisory BoardDr. Claude Nicaise M.D.Head of R&DMr. Jason Tardio M.B.A.Chief Operating OfficerDr. Dirk HaasnerSenior Vice President of Global Manufacturing & CMC QAMs. Suzanne K. Wakamoto SHRM-SCP, SPHRSenior Vice President of Culture & FacilitiesDr. Jeremy Max Levin Ba Zoology, Dphil, Mb BchirPres, Chief Executive Officer & ChairmanDr. Julia Tsai Ph.D.Senior Vice President of Clinical Devel.Mr. Simon D. KelnerChief HR OfficerMr. Thomas Michael Perone J.D., M.B.A.Gen. Counsel, Chief Compliance Officer & Corporation Sec.Dr. Todd F. Baumgartner M.D., M.P.H.Senior Vice President of Regulatory AffairsMs. Lora PikeVice President of Investor Relations & CommunicationsDr. Todd F. Baumgartner M.P.H., M.D.Senior Vice President of Regulatory Affairs, Pharmacovigilance & BiometricsMr. Jeffrey A. RonaPrincipal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer

NASDAQ : OVID

Ovid Therapeutics

$2.73

-0.03-1.09%

At Close 4:00 PM

57.48

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Ovid Therapeutics Inc. (OVID) stock declined over -1.09%, trading at $2.73 on NASDAQ, down from the previous close of $2.76. The stock opened at $2.68, fluctuating between $2.53 and $2.74 in the recent session.

Stock Snapshot

2.76

Prev. Close

360.04M

Market Cap

2.525

Day Low

-9.41

P/E Ratio

-0.29

EPS (TTM)

-0.65

Cash Flow per Share

2.68

Open

131.88M

Number of Shares

2.74

Day High

83.71%

Free Float in %

1.24

Book Value

3.03M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 08, 2026	2.68	2.74	2.53	2.73	3.03M
Jul 07, 2026	2.64	2.82	2.49	2.76	3.31M
Jul 06, 2026	2.77	2.77	2.60	2.61	1.16M
Jul 02, 2026	2.71	2.80	2.63	2.69	1.89M
Jul 01, 2026	2.66	2.72	2.61	2.68	1.41M
Jun 30, 2026	2.70	2.84	2.64	2.69	2.97M
Jun 29, 2026	2.52	2.73	2.46	2.72	1.54M
Jun 26, 2026	2.40	2.60	2.39	2.55	22.55M
Jun 25, 2026	2.49	2.55	2.38	2.42	2.14M
Jun 24, 2026	2.31	2.53	2.29	2.50	2.8M
Jun 23, 2026	2.20	2.33	2.19	2.32	2.42M
Jun 22, 2026	2.32	2.37	2.22	2.25	2.57M
Jun 18, 2026	2.42	2.49	2.27	2.27	15.35M
Jun 17, 2026	2.34	2.48	2.34	2.42	3.86M
Jun 16, 2026	2.25	2.41	2.24	2.36	2.36M
Jun 15, 2026	2.27	2.34	2.22	2.26	1.84M
Jun 12, 2026	2.20	2.36	2.19	2.30	2.06M
Jun 11, 2026	2.28	2.39	2.16	2.21	2.88M
Jun 10, 2026	2.42	2.50	2.27	2.28	1.61M
Jun 09, 2026	2.39	2.45	2.33	2.42	1.48M

Contact Details

New York City, NY 10036

United States

https://www.ovidrx.com 646 661 7661

About Company

Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.

Stock Peers

ARGX

-4.64-0.50%

argenx SE$915.30 REGN

-13.35-1.97%

Regeneron Pharmaceuticals, Inc.$662.88 MDGL

20.04+3.67%

Madrigal Pharmaceuticals, Inc.$565.40 UTHR

-9.36-1.66%

United Therapeutics Corporation$554.34 VRTX

-23.82-4.56%

Vertex Pharmaceuticals Incorporated$498.43 KRYS

6.8+1.84%

Krystal Biotech, Inc.$375.40 PRAX

9.04+2.79%

Praxis Precision Medicines, Inc.$332.99 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.91+0.59%

Alnylam Pharmaceuticals, Inc.$323.50 LGND

-4.55-1.42%

Ligand Pharmaceuticals Incorporated$314.88

Company Overview

Ovid Therapeutics Inc. (NASDAQ:OVID) closed at $2.73 USD, losing -$0.03 (-1.09%) from the previous close of $2.76. The stock is currently mid-range between its 52-week high and low $0.36 and $3.10. With a market capitalization of about $360.04 million, Ovid Therapeutics Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.19). Key stats such as the average daily volume over the past year has been around 2.71 million shares, in line with its 52-week average. Headquartered in New York City, NY, Ovid Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Margaret Alexander, the company employs approximately 23 people and listed since May 05, 2017. Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 8.06%, SMA50 2.94%, SMA200 46.69%). The stock’s 14-day RSI is 56.14 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.91% below its high and over 580.41% above its low. Average 10-day trading volume of 2.19 million shares is below the 3-month average of 2.76 million, indicating normal recent market interest.

Valuation Metrics

Ovid Therapeutics Inc. trades at a P/E ratio of -7.81, slightly below the S&P 500 average, with a price-to-sales ratio of 50.04 and a price-to-book ratio of 1.01 suggesting the stock is closer to book value. The P/FCF stands at -8.5, also below market averages.

Dividend & Fair Value

Ovid Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.96. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Ovid Therapeutics Inc. generated EPS of -$0.51 over the past year. Five-year average earnings growth is 24.72%. Wall Street analysts project EPS growth of -13.2% annually over the next five years. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.12. Next year's EPS is expected at $14.01. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $2.00. The high target offers 156.41% upside. The low target suggests -26.74% downside. The mean target is $4.22. This offers 54.58% upside. Ovid Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 0.0%. The prior quarter beat by -160.0%. Over the last six quarters, Apple has recorded several small beats. These include -18.75% in March 11, 2025.

Shareholding & Insider Activity

Ovid Therapeutics Inc. has 71.11 million shares outstanding. The public float is 59.52 million shares, elevated short interest at 2.70% of float. This equals 1.61 million shares. The short ratio is 0.69 days. Institutional investors hold 41.45% of the float. Insiders own 16.31%. TAKEDA PHARMACEUTICAL CO LTD holds 5.75 million shares, Rakhit Amit has 726.82 thousand shares and Rona Jeffrey A has 88.19 thousand shares. Over the past six months, insider transactions show net selling. They sold 20.20 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Ovid Therapeutics generated $391.70K in revenue, or $0.01 per share. Gross margin was -307.61%, operating margin -15134.60%, and net profit margin -13362.17%. Returns are negative, with ROA at -36.34% and ROE at -59.61%.
On valuation metrics, Ovid Therapeutics trades at a P/E of -7.81, P/S of 50.04 and P/B of 1.01. The current ratio is 10.17 and quick ratio is 10.17. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -92564.00 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -28.75.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Ovid Therapeutics posted revenue of $391.70K, down slightly from $1.50M in the prior quarter. Gross profit was - $1.20M (margin -307.61%). Operating income was - $59.28M (margin -15134.6%). Net income was- $52.34M (EPS - $0.74).
The company ended the quarter with $105.83M in cash and short-term investments, a total debt of $46.00M, and net debt of $18.96M. Total assets were $144.03M, with equity of $87.80M. Financials further reflected weakness, with operating cash flow of - $45.78M, free cash flow of - $45.92M, and capital expenditures of - $137.46K.

Price Forecast & Outlook

Our AI price prediction model suggests that Ovid Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.06%, with price expected at $2.95 by July 22, 2026, within a range of $2.81 to $3.08 3-Month Outlook: Projected rise of 148.72%, reaching $6.79 by October 06, 2026, with a range of $6.76 to $6.84. 1-Year Outlook: Projected gain of 890.11%, with price at $27.03 by July 08, 2027, within a range of $24.90 to $36.79.

Key Takeaways

Ovid Therapeutics Inc. (NASDAQ:OVID) shares are flat -6.75% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Ovid Therapeutics Inc. trading at a premium to the broader market with a P/E of -7.81. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $5.79, suggesting 112.09% upside. Our AI forecast model points to short-term strength (8.06% over two weeks), a medium-term rise (148.72% over three months), and a longer-term gain (890.11% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Ovid Therapeutics Inc. (OVID) stock price?

Ovid Therapeutics Inc. (NASDAQ: OVID) stock price is $2.73 in the last trading session. During the trading session, OVID stock reached the peak price of $2.74 while $2.53 was the lowest point it dropped to. The percentage change in OVID stock occurred in the recent session was -1.09% while the dollar amount for the price change in OVID stock was - $0.03.

OVID's industry and sector of operation?

The NASDAQ listed OVID is part of Biotechnology industry that operates in the broader Healthcare sector. Ovid Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of OVID?

Dr. Matthew J. During DSc, FACP, FRACP, M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Claude Nicaise M.D.
Head of R&D
Mr. Jason Tardio M.B.A.
Chief Operating Officer
Dr. Dirk Haasner
Senior Vice President of Global Manufacturing & CMC QA
Ms. Suzanne K. Wakamoto SHRM-SCP, SPHR
Senior Vice President of Culture & Facilities
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
Pres, Chief Executive Officer & Chairman
Dr. Julia Tsai Ph.D.
Senior Vice President of Clinical Devel.
Mr. Simon D. Kelner
Chief HR Officer
Mr. Thomas Michael Perone J.D., M.B.A.
Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Dr. Todd F. Baumgartner M.D., M.P.H.
Senior Vice President of Regulatory Affairs
Ms. Lora Pike
Vice President of Investor Relations & Communications
Dr. Todd F. Baumgartner M.P.H., M.D.
Senior Vice President of Regulatory Affairs, Pharmacovigilance & Biometrics
Mr. Jeffrey A. Rona
Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer

How OVID did perform over past 52-week?

OVID's closing price is 658.33% higher than its 52-week low of $0.36 where as its distance from 52-week high of $3.11 is -12.08%.

How many employees does OVID have?

Number of OVID employees currently stands at 23.

Link for OVID official website?

Official Website of OVID is: https://www.ovidrx.com

How do I contact OVID?

OVID could be contacted at phone 646 661 7661 and can also be accessed through its website. OVID operates from 1460 Broadway, New York City, NY 10036, United States.

How many shares of OVID are traded daily?

OVID stock volume for the day was 3.03M shares. The average number of OVID shares traded daily for last 3 months was 2.71M.

What is the market cap of OVID currently?

The market value of OVID currently stands at $360.04M with its latest stock price at $2.73 and 131.88M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	23
Beta	0.18
Sales or Revenue	$391.70K
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

OVID Company Profile and Key Details

Ovid Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways